{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Stereotaxis, Inc.
Stereotaxis, Inc. Hits New 52-Week High at USD 3.37
Stereotaxis, Inc. has achieved a new 52-week high of USD 3.37, contrasting with its 52-week low of USD 1.54. Despite this milestone, the company has seen a 1-year performance decline of 11.17%. Currently, Stereotaxis is loss-making, with a market capitalization of USD 262 million.
Stereotaxis, Inc. Hits New 52-Week High at $3.33
Stereotaxis, Inc. has achieved a new 52-week high of USD 3.33 as of October 6, 2025, despite a 1-year performance decline of 7.82%. The company, with a market capitalization of USD 262 million, is currently loss-making and does not offer dividends, reflecting challenges in the Pharmaceuticals & Biotechnology sector.
Stereotaxis, Inc. Hits New 52-Week High at USD 3.20
Stereotaxis, Inc. has achieved a new 52-week high of USD 3.20 as of October 1, 2025, significantly up from its low of USD 1.54. The company, with a market cap of USD 262 million, is currently loss-making and has a high price-to-book ratio, reflecting its challenging financial position.
Stereotaxis, Inc. Hits New 52-Week High of $3.07
Stereotaxis, Inc. has achieved a new 52-week high of USD 3.07, contrasting with a low of USD 1.54. Despite this milestone, the company has seen a 1-year performance decline of 18.16%. With a market cap of USD 262 million, Stereotaxis remains loss-making and faces challenges in the competitive pharmaceuticals sector.
Is Stereotaxis, Inc. technically bullish or bearish?
As of August 8, 2025, Stereotaxis, Inc. shows a bullish technical trend supported by positive MACD and moving averages, despite a bearish weekly RSI and mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over the past year, but underperforming over longer periods.
Is Stereotaxis, Inc. overvalued or undervalued?
As of May 9, 2019, Stereotaxis, Inc. is considered a risky investment due to its high Price to Book Value of 23.67, negative EV to EBIT and EV to EBITDA ratios, and a low Return on Equity of -310.19%, especially when compared to peers like Bioventus and Semler Scientific, despite a year-to-date return of 22.81% against the S&P 500's 12.22%.
Is Stereotaxis, Inc. overvalued or undervalued?
As of May 9, 2019, Stereotaxis, Inc. is considered overvalued and risky, with a price-to-book ratio of 23.67, an EV to EBITDA of -7.42, and a year-to-date return of -7.46%, significantly underperforming compared to the S&P 500's 2.44%.
Is Stereotaxis, Inc. technically bullish or bearish?
As of June 20, 2025, the technical trend has shifted to mildly bearish, with daily moving averages and weekly Dow Theory indicating bearish signals, while mixed signals from other indicators suggest caution.
Who are in the management team of Stereotaxis, Inc.?
As of March 2022, the management team of Stereotaxis, Inc. includes Chairman and CEO David Fischel, Lead Independent Director David Benfer, Directors Nathan Fischel, Joseph Kiani, Ross Levin, and Independent Director Arun Menawat. They oversee the company's strategic direction and governance.
What does Stereotaxis, Inc. do?
Stereotaxis, Inc. is a U.S. healthcare technology company specializing in robotic cardiology instrument navigation systems, with a market cap of $195.23 million and recent net sales of $7 million. The company reported a net loss of $6 million for the quarter ending March 2025.
How big is Stereotaxis, Inc.?
As of Jun 18, Stereotaxis, Inc. has a market capitalization of 195.23 million and reported net sales of 27.51 million, with a net loss of 25.35 million over the latest four quarters. Shareholder's funds are at 11.43 million, and total assets amount to 46.72 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
